Literature DB >> 24759621

Epigenetic silencing of RASSF10 promotes tumor growth in esophageal squamous cell carcinoma.

Di Lu1, Jun Ma, Qimin Zhan, Yin Li, Jianjun Qin, Mingzhou Guo.   

Abstract

UNLABELLED: Esophageal squamous cell carcinoma (ESCC) is one of the most malignant diseases and the five year survival rate remains less than 10%. RASSF10 is a newly identified member of the Ras-association family, but the regulation and the function of RASSF10 in ESCC remain unclear. Research methodologies such as methylation specific PCR (MSP), semi-quantitative RT-PCR, immunohistochemistry, Sodium bisulfite sequencing, and colony formation assay were utilized in this investigation. Loss of RASSF10 expression was found in KYSE150 cells and reduced expression was found in KYSE70 and KYSE180 cells. Expression of RASSF10 was found in KYSE140, KYSE450, KYSE510, TE1, TE3, and TE8 cell lines. Complete methylation was found in KYSE30 and KYSE150 cells, partial methylation was found in KYSE70, KYSE180, KYSE510, and TE1, and unmethylation was found in KYSE140, KYSE450, TE3, and TE8. Re-expression or increased expression was induced by 5-Aza-dC treatment. RASSF10 was methylated in 44.3% primary esophageal squamous cell carcinoma. RASSF10 inhibits cell proliferation and induces G2/M phase arrest in esophageal cancer cells. IN
CONCLUSION: RASSF10 was frequently methylated in human esophageal squamous cell carcinoma and expression of RASSF10 was regulated by promoter region hypermethylation. RASSF10 may serve as a tumor suppressor of esophageal cancer.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 24759621

Source DB:  PubMed          Journal:  Discov Med        ISSN: 1539-6509            Impact factor:   2.970


  11 in total

1.  Pancreatic cancer patient survival correlates with DNA methylation of pancreas development genes.

Authors:  Michael J Thompson; Liudmilla Rubbi; David W Dawson; Timothy R Donahue; Matteo Pellegrini
Journal:  PLoS One       Date:  2015-06-03       Impact factor: 3.240

2.  RASSF10 suppresses hepatocellular carcinoma growth by activating P53 signaling and methylation of RASSF10 is a docetaxel resistant marker.

Authors:  Yongshuai Jin; Baoping Cao; Meiying Zhang; Qimin Zhan; James G Herman; Miao Yu; Mingzhou Guo
Journal:  Genes Cancer       Date:  2015-05

3.  RASSF10 suppresses colorectal cancer growth by activating P53 signaling and sensitizes colorectal cancer cell to docetaxel.

Authors:  Jing Guo; Yage Yang; Yunsheng Yang; Enqiang Linghu; Qimin Zhan; Malcolm V Brock; James G Herman; Bingyong Zhang; Mingzhou Guo
Journal:  Oncotarget       Date:  2015-02-28

4.  Predictive value of the serum RASSF10 promoter methylation status in gastric cancer.

Authors:  Yilin Hu; Peng Ma; Ying Feng; Peng Li; Hua Wang; Yibing Guo; Qinsheng Mao; Wanjiang Xue
Journal:  J Int Med Res       Date:  2019-05-23       Impact factor: 1.671

5.  Integration of intratumoral RASSF10 expression and tumor-associated macrophages into the established clinical indicators better predicts the prognosis of clear cell renal cell carcinoma patients.

Authors:  Chao Wang; Tianyu Hong; Yuning Wang; Sishun Gan; Qifeng Wang; Jian Li; Li Zuo; Xingang Cui
Journal:  Oncoimmunology       Date:  2020-03-11       Impact factor: 8.110

Review 6.  The detective, prognostic, and predictive value of DNA methylation in human esophageal squamous cell carcinoma.

Authors:  Kai Ma; Baoping Cao; Mingzhou Guo
Journal:  Clin Epigenetics       Date:  2016-04-22       Impact factor: 6.551

7.  RASSF10 is an epigenetically inactivated tumor suppressor and independent prognostic factor in hepatocellular carcinoma.

Authors:  Fei Wang; Ying Feng; Peng Li; Kun Wang; Liang Feng; Yi-Fei Liu; Hua Huang; Yi-Bing Guo; Qin-Sheng Mao; Wan-Jiang Xue
Journal:  Oncotarget       Date:  2016-01-26

8.  Ras-association domain family 10 acts as a novel tumor suppressor through modulating MMP2 in hepatocarcinoma.

Authors:  W Liu; J Wang; L Wang; C Qian; Y Qian; H Xuan; W Zhuo; X Li; J Yu; J Si
Journal:  Oncogenesis       Date:  2016-06-27       Impact factor: 7.485

Review 9.  Aberrant DNA Methylation in Esophageal Squamous Cell Carcinoma: Biological and Clinical Implications.

Authors:  Lehang Lin; Xu Cheng; Dong Yin
Journal:  Front Oncol       Date:  2020-10-23       Impact factor: 6.244

10.  RASSF9 promotes NSCLC cell proliferation by activating the MEK/ERK axis.

Authors:  Jun Yuan; Qianqian Ju; Jun Zhu; Yun Jiang; Xuechao Yang; Xiaoyu Liu; Jinyu Ma; Cheng Sun; Jiahai Shi
Journal:  Cell Death Discov       Date:  2021-07-31
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.